SCHEMBL1649341

SCHEMBL1649341

COc1c(-c2ccoc2)ccc(CSc2ccccc2)c1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.47
KMT2A Q03164 1/20 0.41
SLC37A4 O43826 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TUBB4A P04350 5/20 0.37
TUBB P07437 5/20 0.37
TUBA3C P0DPH7 5/20 0.37
TUBA1B P68363 5/20 0.37
TUBA4A P68366 5/20 0.37
TUBB4B P68371 5/20 0.37
TUBB3 Q13509 5/20 0.37
TUBB2A Q13885 5/20 0.37
TUBB8 Q3ZCM7 5/20 0.37
TUBA3E Q6PEY2 5/20 0.37
TUBA1A Q71U36 5/20 0.37
TUBA1C Q9BQE3 5/20 0.37
TUBB6 Q9BUF5 5/20 0.37
TUBB2B Q9BVA1 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648250 0.91 METAP2 (0.43) METAP2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL18801306 0.90 METAP2 (0.56) METAP2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL18801304 0.89 METAP2 (0.49) METAP2KMT2ASLC37A4TUBB4ATUBB
SCHEMBL18801057 0.89 METAP2 (0.42) METAP2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL18801277 0.89 CYP2C9 (0.42) METAP2KMT2ASLC37A4TUBB4ATUBB
SCHEMBL1649106 0.88 METAP2 (0.39) METAP2KMT2ASLC37A4NPC1RAB9A
SCHEMBL18801059 0.87 KMT2A (0.42) KMT2ASLC37A4NPC1RAB9ASMN1; SMN2
SCHEMBL18801075 0.87 KMT2A (0.40) METAP2KMT2ASLC37A4FABP4FABP5
SCHEMBL1648474 0.87 METAP2 (0.38) METAP2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL18801061 0.86 METAP2 (0.43) METAP2KMT2ARAB9ASMN1; SMN2TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS METAP2 1/4885KMT2A 666/4885SLC37A4 1981/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS METAP2 1/4885KMT2A 666/4885SLC37A4 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.